Gene correction in hematopoitic stem cells using a retargetable meganuclease
Gene correction in hematopoitic stem cells using a retargetable meganuclease
批准号:
7744710
负责人:
Michael J Volles
金额:
$5.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-01-01 至 2010-12-31
关键词:
AminoglycosidesBiological AssayBloodBlood CellsBone MarrowBone Marrow PurgingBone Marrow TransplantationCancer EtiologyCell FractionCell TransplantsCellsChromosomesCleaved cellDataDisadvantagedDiseaseDrug FormulationsElectroporationEmbryoEngineeringEnzymesEventFibroblastsFlow CytometryFrequenciesGene TargetingGenesGenomeGreen Fluorescent ProteinsHematological DiseaseHematopoieticHematopoietic stem cellsHomingImageIndividualInheritedLifeLocationLuciferasesMammalian CellMeasuresMethodsModelingMonitorMouse Cell LineMusMutationPlasmidsPopulationProceduresProteinsProtocols documentationPublishingRegulationRegulatory ElementRelative (related person)RetroviridaeSamplingSideSiteSorting - Cell MovementSpecificityStem cellsSubfamily lentivirinaeTimeToxic effectTransfectionTransgenesTransgenic OrganismsTransplant RecipientsTransplantationVariantWild Type Mouseantibiotic G 418basecell growthcongenicdesignendonucleaseestablished cell linegene correctiongene therapyhomologous recombinationin vivolentiviral integrationlipofectionmammalian genomemouse genomemutantreconstitutionresearch studystemtherapeutic transgenetransgene expressionvector
中文摘要
描述(由申请人提供):在分裂细胞如造血干细胞中的持续基因治疗通常需要将治疗性转基因整合到染色体中,例如,使用逆转录病毒。这种方法有几个缺点,包括在不合适的基因座整合可能导致癌症,以及缺乏适当的基因调控元件。相比之下,通过同源重组的基因靶向允许将转基因置于基因组中预定的安全位置。利用基因靶向进行基因治疗的困难在于,它在大多数细胞中很少发生。然而,先前已经表明,在待靶向的位点处引入双链断裂可以使哺乳动物细胞中的同源重组频率增加多达五个数量级。该提议试图定义用特异性切割小鼠基因组中ROSA 26基因座的可重靶向核酸内切酶诱导基因靶向的最佳方法。ROSA 26是转基因表达的理想位点,因为它广泛表达且非必需。核酸内切酶来源于ICrel酶,并且具有足够的特异性以能够靶向哺乳动物基因组中的特定位点,并且是足够可修饰的,使得其可以被设计为靶向大多数基因座。首先,将证明工程化核酸内切酶在小鼠细胞系中诱导基因靶向的能力。将使用绿色荧光蛋白作为模型转基因。第二,将确定诱导造血干细胞中基因校正同时保持其重建骨髓清除个体血液的能力的最佳方法。最后,将开发用于增加造血细胞移植中正确靶向的细胞的分数的方法,该方法基于在移植前培养中的扩增和用流式细胞术分选的选择。目前旨在通过基因治疗某些遗传性血液病的方法存在缺陷,例如可能导致癌症和疗效低下。该提案旨在定义新的方法,以更精确地纠正导致这些疾病的遗传突变,从而消除当前基因治疗方案的一些危险和缺点。
英文摘要
DESCRIPTION (provided by applicant): Persistent gene therapy in dividing cells such as hematopoietic stem cells generally requires that the therapeutic transgene be integrated into a chromosome, for example, using a retrovirus. There are several drawbacks to this approach, including the possibility that integration at an inopportune locus can cause cancer, and a lack of appropriate gene regulatory elements. In contrast, gene targeting by homologous recombination allows one to place a transgene into a predetermined, safe, location in the genome. The difficulty in making use of gene targeting for gene therapy is that it occurs only rarely in most cells. However, it has previously been shown that introducing a double strand break at the site to be targeted can increase the homologous recombination frequency by up to five orders of magnitude in mammalian cells. This proposal seeks to define optimal methods for inducing gene targeting with a retargetable endonuclease that specifically cuts at the ROSA26 locus in the mouse genome. ROSA26 is an ideal site for transgene expression because it is ubiquitously expressing and non-essential. The endonuclease is derived from the ICrel enzyme and has sufficient specificity to be able to target particular sites in a mammalian genome, and is sufficiently modifiable that it can be designed to target most loci. First, the ability of the engineered endonuclease to induce gene targeting in mouse cell-lines will be demonstrated. Green fluorescent protein will be used as a model transgene. Second, optimal methods to induce gene correction in hematopoietic stem cells while maintaining their ability to reconstitute the blood of a myelpablated individual will be determined. Finally, methods for increasing the fraction of correctly targeted cells in a hematopoietic cell transplant, based on expansion in culture and selection with flow cytometry sorting prior to transplant, will be developed. Current methods aimed at genetically curing certain inherited blood diseases have drawbacks, such as the possibility of causing cancer and low efficacy. This proposal seeks to define new methods to more precisely correct the inherited mutations that cause these disorders, thereby eliminating some of the dangers and disadvantages of current gene therapy protocols.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gene correction in hematopoitic stem cells using a retargetable meganuclease
-
批准号:7558494
-
项目类别:
-
资助金额:$5.53万
-
财政年份:2008
-
负责人:Michael J Volles
-
依托单位:
Gene correction in hematopoitic stem cells using a retargetable meganuclease
-
批准号:7409424
-
项目类别:
-
资助金额:$5.29万
-
财政年份:2008
-
负责人:Michael J Volles
-
依托单位:
海外基金